China Ulcerative Colitis Market, By Drug Therapy, By Dosage Form, By Distribution Channel

China Ulcerative Colitis Market is estimated to be valued at USD 280.9 Mn in 2026 and is expected to reach USD 352.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.3% from 2026 to 2033.

Ulcerative colitis is the most common type of inflammatory bowel disease that affects the colon (lining of the large intestine) and rectum. The inflammation produces tiny sores called ulcers. This disease can affect people of any age. The major symptoms of this disease include diarrhea, belly pain/cramps, bleeding from the rectum, also other indications include sudden and unexplained weight loss, loss of appetite, joint pain, eye disease, thickening of the intestinal wall, blood infection (sepsis), kidney stones, and liver disease. The diagnosis of this disease can be carried out by physical examination using tests such as colonoscopy, endoscopy, biopsy, CT scan, and blood test. If ulcerative colitis persists for over eight years or longer, it may lead to colon cancer.

The people having mild symptoms of this disease can be cured by over-the-counter drugs such as Imodium therapy. However, transcription medicine such as steroid medicines and amino salicylates are widely used to treat the condition. In severe cases, the patient may need to undergo surgery to remove the colon, which also helps to prevent colon cancer. The exact cause for ulcerative colitis is unknown, though possible reasons are may be genetic factors, environmental changes, or weakened immune system.

Market Dynamics

Market players are engaged in receiving approvals from the regulatory authorities, this is expected to drive the growth of the China ulcerative colitis market, over the forecast period. For instance, in 2019, in April, AbbVie announced that the U.S. Food and Drug Administration approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. The drug Risankizumab is the product of a partnership between Boehringer Ingelheim, a research driven pharmaceutical company and AbbVie.

Moreover, in 2019, Janssen Biotech, Inc., a subsidiary of Johnson & Johnson received the U.S. Food and Drug Administration (FDA) approval for STELARA (ustekinumab) for the treatment of adult patients with moderate-to-severe active ulcerative colitis.

Key players are focusing on conducting research and development activities for finding the treatment for the ulcerative colitis and this is expected to increase the growth of the China ulcerative colitis market, over the forecast period. For instance, In August, InDex Pharmaceuticals Holding AB announced positive top line results from the dose optimization study CONDUCT (Cobitolimod as Novel DNA-based Ulcerative Colitis Treatment), which evaluated cobitolimod for the treatment of moderate to severe ulcerative colitis

Key features of the study

• This report provides an in-depth analysis of the China ulcerative colitis market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the China ulcerative colitis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include AbbVie Inc, Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen Inc., BRISTOL-MYERS SQUIBB, ZERIA Pharmaceutical Co., Ltd., InDex Pharmaceuticals Holding AB, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., EA Pharma Co., Ltd., Theravance Biopharma, and HUTCHMED
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The China ulcerative colitis market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the China ulcerative colitis market

Market Segmentation

• By Drug Therapy
  • 5-Aminosalicylates
  • Mesalazine
  • Balsalazide
  • Olsalazine
  • Others
  • Monoclonal Antibodies
  • Vedolizumab
  • Adalimumab
  • Infliximab
  • Golimumab
  • Ustekinumab
  • Steroids
  • Budesonide
  • Prednisone
  • Beclomethasone
  • Deflazacort
  • Others
  • Antibiotics
  • Late-Stage Pipeline Molecules
  • Zeposia
  • Etrasimod
  • Others
  • Other Drugs
• By Dosage Form
  • Oral
  • Parenteral
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Key Players
  • AbbVie Inc
  • Celltrion Healthcare
  • Johnson & Johnson Services, Inc.
  • Hoffmann-La Roche AG
  • Arena Pharmaceuticals
  • Takeda Pharmaceuticals Company Ltd.
  • GlaxoSmithKline Plc.
  • Eli Lilly and Company
  • AstraZeneca
  • Pfizer Inc.
  • Amgen Inc.
  • BRISTOL-MYERS SQUIBB
  • ZERIA Pharmaceutical Co., Ltd.
  • InDex Pharmaceuticals Holding AB
  • Mitsubishi Tanabe Pharma Corporation
  • Salix Pharmaceuticals
  • Boehringer Ingelheim International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • EA Pharma Co., Ltd.
  • Theravance Biopharma
  • HUTCHMED